Overview

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Status:
Recruiting

Trial end date:
2026-03-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of RO7247669 (PD1-LAG3) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

Phase:

Phase 2

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Axitinib
Pembrolizumab